First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
暂无分享,去创建一个
Gary A Ulaner | Pat B Zanzonico | D. Lake | Jason S. Lewis | K. Jhaveri | P. Zanzonico | B. Zeglis | C. Riedl | G. Ulaner | J. O’Donoghue | Jason S Lewis | Shutian Ruan | S. Ruan | Komal Jhaveri | Serge K Lyashchenko | Christopher Riedl | Diana Lake | Brian Zeglis | Joseph A O'Donoghue | S. Lyashchenko | Jason S. Lewis | Brian M. Zeglis
[1] Marleen Keyaerts,et al. Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer , 2013, The Journal of Nuclear Medicine.
[2] Serge K. Lyashchenko,et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[4] Jason S. Lewis,et al. Standardized methods for the production of high specific-activity zirconium-89. , 2009, Nuclear medicine and biology.
[5] Adrian V. Lee,et al. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases , 2017, JAMA oncology.
[6] P. Jurek,et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.
[7] W. Weber,et al. Molecular Imaging of Biomarkers in Breast Cancer , 2016, The Journal of Nuclear Medicine.
[8] S. Larson,et al. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer , 2018, The Journal of Nuclear Medicine.
[9] S. Behr,et al. Quantitative and Visual Assessments toward Potential Sub-mSv or Ultrafast FDG PET Using High-Sensitivity TOF PET in PET/MRI , 2018, Molecular Imaging and Biology.
[10] Serge K. Lyashchenko,et al. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT , 2016, The Journal of Nuclear Medicine.
[11] C Cobelli,et al. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. , 1998, Metabolism: clinical and experimental.
[12] C. Vanhove,et al. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma , 2016, The Journal of Nuclear Medicine.
[13] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[14] Y. Erdi,et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. , 2000, Medical physics.
[15] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[16] R. Pierce,et al. Evaluation of 89Zr-pertuzumab in Breast Cancer Xenografts , 2014, Molecular pharmaceutics.
[17] S. Vandenberghe,et al. Optimization of an ultralow-dose high-resolution pediatric PET scanner design based on monolithic scintillators with dual-sided digital SiPM readout: a simulation study , 2017, Physics in medicine and biology.
[18] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[19] Michael G Stabin,et al. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] M. Lubberink,et al. First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule , 2014, The Journal of Nuclear Medicine.
[21] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.